BCG::ESX-1Mmar
Candidate Overview
BCG::ESX-1Mmar is a recombinant BCG strain into which the extended region of the ESX-1-encoding genomic region of Mycobacterium marinum was integrated.
Sponsor / Lead Developer: Institut Pasteur Paris
Primary Indication: Prevention of TB disease
Other Indication(s): Prevention of Mtb infection or sustained infection, Prevention of TB disease, and Prevention of TB recurrence
Target Population(s): Adolescents, Adults, Children, and Infants
Target Route of Administration: Intradermal
Immune tissue localization: Lung and Lymph node
Immunological responses: T-cell
Preclinical Animal Models: Guinea pig and Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ Induction of cytosolic immune signalling | |
| Preferential immune tissue localization | Lung Lymph node | |
| Trained immunity | Yes |
Related Publications
Additional Information
The vaccine candidate is used in the framework of the EU-supported TBVAC-Horizon project.